Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Techne (TECH) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets compani ...

Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.95%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.22, delivering a surprise of +4.35%.Over the last four quarters, the company has s ...

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) is currently viewed as a more attractive investment compared to argenex SE (ARGX) due to its stronger earnings outlook and better valuation metrics [1][3][7] Valuation Metrics - HRMY has a forward P/E ratio of 9.48, significantly lower than ARGX's forward P/E of 29.52, indicating that HRMY may be undervalued [5] - The PEG ratio for HRMY is 0.35, while ARGX has a PEG ratio of 0.72, suggesting that HRMY offers better value relative to its expected earnings growth [5] - HRMY's P/B ratio stands at 2.61, compared to ARGX's P/B of 8.36, further highlighting HRMY's superior valuation [6] Investment Ratings - HRMY holds a Zacks Rank of 1 (Strong Buy), while ARGX has a Zacks Rank of 3 (Hold), indicating a more favorable investment outlook for HRMY [3][7] - Based on the valuation metrics and earnings outlook, HRMY is considered the superior value option at this time [7]

Company Overview - Sutro Biopharma, Inc. (STRO) shares increased by 11.9% to $15.64 in the last trading session, with a notable trading volume, and have gained 23.4% over the past four weeks [1][2] Financial Position - The stock price surge is attributed to a major underwritten offering of shares, which enhances the company's financial position and extends its cash runway for ongoing clinical studies and pipeline advancement [2] - The company is advancing multiple candidates with best-in-class potential targeting complex tumor types where competition is limited [2] Earnings Expectations - Sutro Biopharma is expected to report a quarterly loss of $4.66 per share, reflecting a year-over-year increase of 47.6%, while revenues are projected to be $9.08 million, down 35.2% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Sutro Biopharma operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like TScan Therapeutics, Inc. (TCRX), that closed 1.4% higher at $1, but has seen a return of -16% over the past month [5] - TScan Therapeutics has a consensus EPS estimate of -$0.27 for the upcoming report, representing a year-over-year change of +6.9%, and also holds a Zacks Rank of 3 (Hold) [6]

分组1 - Twist Bioscience reported a quarterly loss of $0.5 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.53 per share a year ago, indicating a surprise of -5.26% [1] - The company generated revenues of $103.7 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.05%, but showing growth from $88.71 million in the same quarter last year [2] - Over the last four quarters, Twist Bioscience has surpassed consensus revenue estimates three times, but only once for EPS estimates [2] 分组2 - The stock has increased by approximately 29.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at -$0.46 for the coming quarter and -$1.64 for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Investors are evaluating CSL Limited Sponsored ADR (CSLLY) and Techne (TECH) to determine which stock offers better value for investment at the current time [1] Group 1: Zacks Rank and Earnings Outlook - CSLLY has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while TECH has a Zacks Rank of 4 (Sell), suggesting a less favorable outlook [3] - The improving earnings outlook for CSLLY positions it as a more attractive option for value investors [7] Group 2: Valuation Metrics - CSLLY has a forward P/E ratio of 18.08, significantly lower than TECH's forward P/E of 32.34, indicating that CSLLY may be undervalued [5] - The PEG ratio for CSLLY is 1.77, while TECH's PEG ratio is 3.72, further suggesting that CSLLY offers better value considering expected earnings growth [5] - CSLLY's P/B ratio is 2.88 compared to TECH's P/B of 5.07, reinforcing the notion that CSLLY is more attractively priced relative to its book value [6] - Based on these valuation metrics, CSLLY holds a Value grade of B, while TECH has a Value grade of D, indicating a stronger value proposition for CSLLY [6]

Core Viewpoint - Fortrea Holdings Inc. (FTRE) is currently viewed as a more attractive option for value investors compared to Acadia Pharmaceuticals (ACAD) based on earnings outlook and valuation metrics [3][7]. Valuation Metrics - FTRE has a forward P/E ratio of 22.52, while ACAD has a forward P/E of 35.71, indicating FTRE is potentially undervalued [5]. - The PEG ratio for FTRE is 0.50, suggesting a favorable growth outlook compared to ACAD's PEG ratio of 6.42, which indicates a less attractive growth valuation [5]. - FTRE's P/B ratio stands at 2.68, compared to ACAD's P/B of 4.83, further supporting FTRE's valuation advantage [6]. Earnings Outlook - FTRE has shown a stronger improvement in its earnings outlook compared to ACAD, contributing to its higher Zacks Rank of 2 (Buy) versus ACAD's 3 (Hold) [3][7].

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) shares experienced a 6.3% increase, closing at $14.83, driven by notable trading volume and a 52.6% gain over the past four weeks [1][2]. Group 1: Company Developments - The recent price surge is attributed to increased investor confidence following the FDA's lifting of the clinical hold on the MAGNITUDE-2 study for nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) [2]. - Intellia has aligned with the FDA on study modifications and risk-mitigation measures, including enhanced liver safety monitoring, and plans to resume patient enrollment and dosing promptly [2]. Group 2: Financial Expectations - The company is expected to report a quarterly loss of $0.99 per share, reflecting a year-over-year change of +20.2%, with revenues projected at $11.85 million, down 7.9% from the previous year [3]. - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Group 3: Industry Context - Intellia Therapeutics holds a Zacks Rank of 3 (Hold) within the Zacks Medical - Biomedical and Genetics industry, while Vanda Pharmaceuticals (VNDA), another stock in the same industry, finished 3.1% higher at $8.02 and has returned 8.1% over the past month [5]. - Vanda's consensus EPS estimate has changed +7.7% over the past month to -$2.18, representing a significant year-over-year change of -2625%, and it currently holds a Zacks Rank of 2 (Buy) [6].

Company Overview - Qiagen (QGEN) shares increased by 16.6% to close at $55.45, supported by strong trading volume, contrasting with a 1.9% loss over the past four weeks [1] - The company is set to release its fourth-quarter financial results for 2025 on February 4, with a Zacks Consensus Estimate predicting a revenue growth of 14.2% and an earnings growth of 250% [2] Financial Expectations - Qiagen is expected to report quarterly earnings of $0.62 per share, reflecting a year-over-year decline of 3.1%, while revenues are anticipated to reach $527.96 million, marking a 1.3% increase from the previous year [3] - The consensus EPS estimate for Qiagen has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Qiagen operates within the Zacks Medical - Biomedical and Genetics industry, where CytomX Therapeutics (CTMX) also competes, having closed 0.4% lower at $5.37, but showing a 30.8% return over the past month [4] - CytomX Therapeutics has an unchanged consensus EPS estimate of -$0.08, representing a significant year-over-year decline of 136.4%, and also holds a Zacks Rank of 3 (Hold) [5]

Core Insights - BioMarin Pharmaceutical (BMRN) has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Tarsus Pharmaceuticals, Inc. (TARS), which has a Zacks Rank of 3 (Hold) [3] - Value investors utilize various metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - BMRN has a forward P/E ratio of 10.82, significantly lower than TARS's forward P/E of 71.71, suggesting BMRN is more attractively priced [5] - The PEG ratio for BMRN is 0.54, while TARS has a PEG ratio of 1.26, indicating BMRN's expected earnings growth is more favorable [5] - BMRN's P/B ratio stands at 1.83, compared to TARS's P/B of 9.57, further highlighting BMRN's relative valuation strength [6] Value Grades - BMRN holds a Value grade of A, while TARS has a Value grade of D, indicating BMRN is viewed as the superior value investment based on earnings outlook and valuation metrics [6]